.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Roberto Pili, MD

Articles

Dr. Pili on the Challenges of Translocation RCC

October 8th 2019

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

Dr. Pili on Significance of Entinostat/IL-2 Study in RCC

May 25th 2016

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.